Cargando…
Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor format...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405886/ https://www.ncbi.nlm.nih.gov/pubmed/36009558 http://dx.doi.org/10.3390/biomedicines10082011 |
_version_ | 1784773987410116608 |
---|---|
author | Kamstrup, Peter Sand, Jannie Marie Bülow Ulrik, Charlotte Suppli Janner, Julie Rønn, Christian Philip Rønnow, Sarah Rank Leeming, Diana Julie Jensen, Sidse Graff Wilcke, Torgny Mathioudakis, Alexander G. Miravitlles, Marc Lapperre, Therese Bendstrup, Elisabeth Frikke-Schmidt, Ruth Murray, Daniel D. Itenov, Theis Bossios, Apostolos Nielsen, Susanne Dam Vestbo, Jørgen Biering-Sørensen, Tor Karsdal, Morten Jensen, Jens-Ulrik Sivapalan, Pradeesh |
author_facet | Kamstrup, Peter Sand, Jannie Marie Bülow Ulrik, Charlotte Suppli Janner, Julie Rønn, Christian Philip Rønnow, Sarah Rank Leeming, Diana Julie Jensen, Sidse Graff Wilcke, Torgny Mathioudakis, Alexander G. Miravitlles, Marc Lapperre, Therese Bendstrup, Elisabeth Frikke-Schmidt, Ruth Murray, Daniel D. Itenov, Theis Bossios, Apostolos Nielsen, Susanne Dam Vestbo, Jørgen Biering-Sørensen, Tor Karsdal, Morten Jensen, Jens-Ulrik Sivapalan, Pradeesh |
author_sort | Kamstrup, Peter |
collection | PubMed |
description | Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65–1.48), VWF-N: HR 1.56 (95% CI 1.07–2.27), and VWF-A: HR 0.78 (95% CI 0.52–1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population. |
format | Online Article Text |
id | pubmed-9405886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94058862022-08-26 Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population Kamstrup, Peter Sand, Jannie Marie Bülow Ulrik, Charlotte Suppli Janner, Julie Rønn, Christian Philip Rønnow, Sarah Rank Leeming, Diana Julie Jensen, Sidse Graff Wilcke, Torgny Mathioudakis, Alexander G. Miravitlles, Marc Lapperre, Therese Bendstrup, Elisabeth Frikke-Schmidt, Ruth Murray, Daniel D. Itenov, Theis Bossios, Apostolos Nielsen, Susanne Dam Vestbo, Jørgen Biering-Sørensen, Tor Karsdal, Morten Jensen, Jens-Ulrik Sivapalan, Pradeesh Biomedicines Article Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65–1.48), VWF-N: HR 1.56 (95% CI 1.07–2.27), and VWF-A: HR 0.78 (95% CI 0.52–1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population. MDPI 2022-08-19 /pmc/articles/PMC9405886/ /pubmed/36009558 http://dx.doi.org/10.3390/biomedicines10082011 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kamstrup, Peter Sand, Jannie Marie Bülow Ulrik, Charlotte Suppli Janner, Julie Rønn, Christian Philip Rønnow, Sarah Rank Leeming, Diana Julie Jensen, Sidse Graff Wilcke, Torgny Mathioudakis, Alexander G. Miravitlles, Marc Lapperre, Therese Bendstrup, Elisabeth Frikke-Schmidt, Ruth Murray, Daniel D. Itenov, Theis Bossios, Apostolos Nielsen, Susanne Dam Vestbo, Jørgen Biering-Sørensen, Tor Karsdal, Morten Jensen, Jens-Ulrik Sivapalan, Pradeesh Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title | Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title_full | Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title_fullStr | Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title_full_unstemmed | Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title_short | Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population |
title_sort | biomarkers of clot activation and degradation and risk of future major cardiovascular events in acute exacerbation of copd: a cohort sub-study in a randomized trial population |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405886/ https://www.ncbi.nlm.nih.gov/pubmed/36009558 http://dx.doi.org/10.3390/biomedicines10082011 |
work_keys_str_mv | AT kamstruppeter biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT sandjanniemariebulow biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT ulrikcharlottesuppli biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT jannerjulie biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT rønnchristianphilip biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT rønnowsarahrank biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT leemingdianajulie biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT jensensidsegraff biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT wilcketorgny biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT mathioudakisalexanderg biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT miravitllesmarc biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT lapperretherese biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT bendstrupelisabeth biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT frikkeschmidtruth biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT murraydanield biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT itenovtheis biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT bossiosapostolos biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT nielsensusannedam biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT vestbojørgen biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT bieringsørensentor biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT karsdalmorten biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT jensenjensulrik biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation AT sivapalanpradeesh biomarkersofclotactivationanddegradationandriskoffuturemajorcardiovasculareventsinacuteexacerbationofcopdacohortsubstudyinarandomizedtrialpopulation |